Clinical course of the bony lesion of single-system single-site Langerhans cell histiocytosis – Is appropriate follow-up sufficient treatment?
Authors:
- 1 January 2018
- journal article
- research article
- Published by Elsevier in Journal of Orthopaedic Science
- Vol. 23 (1) , 168-173
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- 18F-Fluorodeoxyglucose PET/CT in Langerhans cell histiocytosis: spectrum of manifestationsJapanese Journal of Radiology, 2016
- Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work‐up, and treatment for patients till the age of 18 yearsPediatric Blood & Cancer, 2012
- Nationwide survey of single‐system single site Langerhans cell histiocytosis in JapanPediatric Blood & Cancer, 2009
- Comparison of FDG‐PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosisPediatric Blood & Cancer, 2008
- Reactivation and risk of sequelae in Langerhans cell histiocytosisPediatric Blood & Cancer, 2007
- Langerhans cell histiocytosisSkeletal Radiology, 2006
- Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosisCancer, 2006
- Langerhans? cell histiocytosis: pathology, imaging and treatment of skeletal involvementPediatric Radiology, 2004
- Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society—Late Effects Study GroupPediatric Blood & Cancer, 2004
- Pattern and course of single‐system disease in Langerhans cell histiocytosis data from the DAL‐HX 83‐ and 90‐studyMedical and Pediatric Oncology, 2001